by aatadmin | Nov 9, 2021 | Amino Acid Therapy, Neurotransmitters, Symptoms of Neurotransmitter Imbalance
One of the most frustrating experiences a person can have is to have symptoms return “out of the blue” after a long period of doing well (i.e., being without symptoms). Luckily, there are several probable reasons that we can identify and correct to get someone back on track and symptom-free ASAP.
by aatadmin | Oct 12, 2021 | Amino Acid Therapy, Parkinson's Disease
One of the most common questions we receive when someone is either considering using amino acids or has gained substantial benefit from amino acid therapy is “how long will I need to continue taking these?” The answer depends on the cause of the underlying imbalance that is being addressed.
by aatadmin | Sep 7, 2021 | Amino Acid Therapy
We have worked with thousands of people all over the world for numerous conditions related to neurotransmitter imbalance(s). Many of these people are currently taking, or have taken one or more medications that alter or affect various neurotransmitters, which can provide us a clue on where to start with amino acid therapy.
by aatadmin | Aug 3, 2021 | Amino Acid Therapy, neurotransmitter testing
The biggest misconception that we run into when using amino acid therapy is how to interpret urinary neurotransmitter results. This post should help clear up some of that confusion.
by aatadmin | Jul 21, 2021 | Amino Acid Therapy, Neurotransmitters, Symptoms of Neurotransmitter Imbalance
We have been working with conditions associated with neurotransmitter imbalance for over two decades. During that time, we have learned a good deal about the most effective strategies to restore optimal neurotransmitter function. One of the most profound discoveries was determining the best way to address the different neurotransmitter systems in the body.
by aatadmin | Jun 16, 2021 | Amino Acid Therapy, Parkinson's Disease
In 2014, Mary Hinz, MD, et al, published a paper that hypothesized that carbidopa depleted the body of vitamin B6 and that this decrease in B6 levels led to progressive neurodegeneration in patients with Parkinson’s disease. Two recent papers provide additional evidence that seems to support that assertion.